Shilpa Medicare’s Pharmaceutical Research & Development (R&D) Unit at Modavalasa in the state of Andhra Pradesh region has received US Food and Drug Administration (USFDA) Establishment Inspection Report (EIR) with intimation of closure of inspection on April 08, 2019.
Earlier, this R&D site has undergone an inspection by the USFDA during February 11, 2019 to February 13, 2019, wherein the company has been issued a Form 483 with one observation.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
